Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.2.1.24: alpha-mannosidase

This is an abbreviated version!
For detailed information about alpha-mannosidase, go to the full flat file.

Word Map on EC 3.2.1.24

Reaction

2-O-alpha-D-mannopyranosyl-D-mannopyranose
+
H2O
= 2 alpha-D-mannopyranose

Synonyms

1,2-alpha-D-mannosidase, 1,2-alpha-mannosidase, acid alpha-mannosidase, acidic alpha-mannosidase, alpha 1,2-mannosidase, Alpha mannosidase 6A8B, alpha-1,2-mannosidase, alpha-1,3 mannosidase, alpha-1,4 mannosidase, alpha-D-mannopyranosidase, alpha-D-mannosidase, Alpha-D-mannoside mannohydrolase, alpha-man, alpha-mann, alpha-mannosidase, alpha-mannosidase C, alpha-mannosidase E-II, alpha-mannosidase I, alpha-mannosidase IA, alpha-mannosidase II, alpha-mannosidase III, alpha1,2-mannosidase, AMAN, class II alpha-mannosidase, CpGH125, ER-alpha-mannosidase, ER-mannosidase II, exo-alpha-mannosidase, GH38 alpha-mannosidase, GH38 alpha-mannosidase II, GH38 class II alpha-mannosidase, GH38 enzyme, Golgi alpha-mannosidase II, Golgi mannosidase IA, Golgi mannosidase IB, Laman, Lysosomal acid alpha-mannosidase, lysosomal alpha-D-mannosidase, lysosomal alpha-mannosidase, Man1p, MAN2B1, Man2C1, Man2C1 alpha-mannosidase, ManA, mannanase, MGG_00994.6, More, neutral alpha-mannosidase, neutral/cytosol mannosidase, p-nitrophenyl-alpha-mannosidase, SpGH125, SpGH38, Ssa-man, SSO3006, TM1851, TMM, velmanase alfa

ECTree

     3 Hydrolases
         3.2 Glycosylases
             3.2.1 Glycosidases, i.e. enzymes that hydrolyse O- and S-glycosyl compounds
                3.2.1.24 alpha-mannosidase

Inhibitors

Inhibitors on EC 3.2.1.24 - alpha-mannosidase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1R,6R,7R,8S)-7,8-dihydroxy-5-thia-1-thioniabicyclo[4.3.0]nonane chloride
-
synthetic inhibitor, selective and potent inhibition at 1 mM, 97% inhibition of the activity of the liver lysosomal fraction at pH 4.0, 100% at pH 6.5
(1S,2R,3R,8R,8aR)-3-[(arylmethoxy)methyl]octahydroindolizine-1,2,8-triol
-
-
(1S,2R,8R,8aR)-octahydroindolizine-1,2,8-triol
(2R,3R,4S)-2-(aminomethyl)pyrrolidine-3,4-diol
(2R,3R,4S)-2-([(1R)-2,3-dihydro-1H-inden-1-ylamino]methyl)pyrrolidine-3,4-diol
-
IC50 is 0.017 mM
(2R,3R,4S)-2-([[(1R)-1-hydroxyethyl]amino]methyl)pyrrolidine-3,4-diol
(2R,3R,4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3,4-diol
(2R,3R,4S)-2-([[(1S)-1-hydroxyethyl]amino]methyl)pyrrolidine-3,4-diol
(2R,3R,4S)-2-hydroxymethyl-pyrrolidine-3,4-diol
(2R,3R,4S)-2-phenylaminomethyl-pyrrolidine-3,4-diol
(2R,3R,4S)-2-[(1-phenyl-ethylamino)-methyl]-pyrrolidine-3,4-diol
(2R,3R,4S)-2-[(benzylamino)methyl]pyrrolidine-3,4-diol
-
IC50 is 0.06 mM
(2R,3R,4S)-2-[(cyclopentylamino)methyl]pyrrolidine-3,4-diol
(2R,3R,4S)-2-[([(1R)-2-benzyloxy-1-phenylethyl]amino)methyl]pyrrolidine-3,4-diol
-
92% inhibition at 1 mM, IC50 is 0.058 mM
(2R,3R,4S)-2-[([(1R)-2-hydroxy-1-phenylethyl]amino)methyl]pyrrolidine-3,4-diol
(2R,3R,4S)-2-[([(1R)-2-methoxy-1-phenylethyl]amino)methyl]pyrrolidine-3,4-diol
-
77% inhibition at 1 mM
(2R,3R,4S)-2-[([(1R,2S)-2-hydroxy-1,2-diphenylethyl]amino)methyl]pyrrolidine-3,4-diol
-
88% inhibition at 1 mM, IC50 is 0.11 mM
(2R,3R,4S)-2-[([(1S)-2-hydroxy-1-phenylethyl]amino)methyl]pyrrolidine-3,4-diol
(2R,3R,4S)-2-[([(1S,2R)-2-hydroxy-1,2-diphenylethyl]amino)methyl]pyrrolidine-3,4-diol
-
84% inhibition at 1 mM, IC50 is 0.128 mM
(2R,3R,4S)-2-[2-(phenylamino)ethyl]pyrrolidine-3,4-diol
-
1 mM, 33% inhibition
(2R,3R,4S)-2-[[(1-benzyl-piperidin-4-ylmethyl)-amino]-methyl]-pyrrolidine-3,4-diol
(2R,3R,4S)-2-[[(2H-Imidazol-1-ylmethyl)-amino]-methyl]-pyrrolidine-3,4-diol
(2R,3R,4S)-2-[[(furan-2-ylmethyl)-amino]-methyl]-pyrrolidine-3,4-diol
(2R,3R,4S)-2-[[(thiophen-2-ylmethyl)-amino]-methyl]-pyrrolidine-3,4-diol
(2R,3R,4S,5R)-2-[(benzylamino)methyl]-5-(hydroxymethyl)pyrrolidine-3,4-diol
-
IC50 is 0.0062 mM
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[([(1R)-2-hydroxy-1,2-diphenylethyl]amino)methyl]pyrrolidine-3,4-diol
-
98% inhibition at 1 mM, IC50 is 0.0042 mM
(2S)-2-[([(2R,3S,4S)-3,4-dihydroxypyrrolidin-2-yl]methyl)amino]-2-phenylethyl 2-fluorobenzoate
(2S)-2-[([(2R,3S,4S)-3,4-dihydroxypyrrolidin-2-yl]methyl)amino]-2-phenylethyl 3-bromobenzoate
(2S)-2-[([(2R,3S,4S)-3,4-dihydroxypyrrolidin-2-yl]methyl)amino]-2-phenylethyl 4-bromobenzoate
(2S)-2-[([(2R,3S,4S)-3,4-dihydroxypyrrolidin-2-yl]methyl)amino]-2-phenylethyl 4-fluorobenzoate
(3R,4R,5R)-3,4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1-methylpyrrolidin-2-one
(3R,4R,5R)-3,4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2-one
(3S,4R)-pyrrolidine-3,4-diol
(6-butoxy-3-oxo-3,6-dihydro-2H-pyran-2-yl)methyl 2,2-dimethylpropanoate
-
-
(6-methoxy-3-oxo-3,6-dihydro-2H-pyran-2-yl)methyl 2,2-dimethylpropanoate
-
-
1,4-Dideoxy-1,4-imino-D-mannitol
-
1,6-dideoxy-1,6-episulfinyl-beta-D-mannose
-
XLM, sulfoxide derivative, thiolevomannosan analog, more potent than kifunensine and deoxymannojirimycin, docking studies with the crystal structure of human alpha-1,2-mannosidase complexed with kifunensine (PDB: 1FO3) as a template
1,6-dideoxy-1,6-episulfonyl-beta-D-mannose
-
NLM, sulfone derivative, thiolevomannosan analog, more potent than kifunensine and deoxymannojirimycin, docking studies with the crystal structure of human alpha-1,2-mannosidase complexed with kifunensine (PDB: 1FO3) as a template
1,6-dideoxy-1,6-epithio-beta-D-mannose
-
thiolevomannosan TLM, docking studies with the crystal structure of human alpha-1,2-mannosidase complexed with kifunensine (PDB: 1FO3) as a template
1-cyclohexyl-3-(2-morpholinyl-4-ethyl)carbodiimide
-
inhibitory at 25 mM, pseudo-first-order kinetic
1-deoxy-mannojirimycin
-
complete inhibition
1-deoxymannojirimicin
1-deoxymannojirimycin
2-(2,2-dihydroxy-ethyl)-pyrrolidine-3,4-diol
2-amino-2-deoxy-D-glucose
-
competitive inhibition, Ki = 2.8 mM
2-deoxy-2-fluoro-alpha-D-mannosyl fluoride
-
for mutant enzyme D341N, no inhibition of wild-type enzyme
3-bromo-N-[(2S)-2-[([(2R,3S,4R)-3,4-dihydroxypyrrolidin-2-yl]methyl)amino]-2-phenylethyl]benzamide
5-fluoro-beta-L-gulosyl fluoride
-
reversible, acts as a slow substrate for the D341 mutant enzyme, with deglycosylation as the rate-limiting step. Inactivation is only observed when assayed at low temperatures such that deglycosylation is slow relative to the assay time
8,8a-di-epi-swainsonine
-
-
8a-epi-swainsonine
-
-
alpha-conglutin
-
11% inhibition at saturation
-
alpha-D-1,2-mannopyranosyl-mannopyranose
-
50% inhibition at 4 mM
alpha-D-1,3-mannopyranosyl-alpha-D-mannopyranose
-
50% inhibition at 18 mM
alpha-D-1,6-mannopyranosyl-mannopyranose
-
50% inhibition at 100 mM
alpha-D-mannopyranose
cysteine
-
31% inhibition at 0.02 mM
D-glucose
-
67% inhibition at 30 mM
D-glucuronic acid
-
slight inhibition at 10 mM
D-mannono-1,4-lactone
D-mannono-1,5-lactone
D-mannono-gamma-lactone
-
-
D-mannosylamine
deoxymannojirimycin
diisopropylfluorophosphate
-
42% inhibition at 10 mM
EGTA
-
32% inhibition at 5 mM
gluco-hydroxyiminolactam
-
-
glucoimidazole
-
-
iodoacetamide
-
slight inhibition at 1 mM
iodoacetic acid
kifunensine
Li+
-
88% inhibition at 20 mM
Mannan
-
33% inhibition at 50 mM
mannoimidazole
-
-
mannose
-
relative inhibition of 67.8%, potent inhibitor, three concentrations of 10, 50, and 100 mM tested
methyl-alpha-D-glucoside
-
23% inhibition at 10 mM
methyl-alpha-D-lyxopyranosyl-(1'-2)-alpha-D-mannopyranoside
-
-
methyl-alpha-D-lyxopyranosyl-(1-2)-alpha-D-mannopyranoside
-
potent
methyl-alpha-D-mannopyranoside
methyl-alpha-mannoside
-
not
N-bromosuccinimide
-
N-bromosuccinimide modified inactivation, effect of Trp modification on enzyme activity
N-octyl-6-epi-valienamine
-
-
Na+
-
1 mM, weak, not at 10 mM
NaN3
-
slight inhibition at 0.1 mM
p-chloromercuribenzenesulfonic acid
p-nitrophenyl-alpha-D-mannopyranoside
-
substrate inhibition greater than 2 mM
SDS
-
85% inhibition at 0.05%, w/v
small interfering RNA
siRNA designed to specifically inhibit Man2C1 gene expression, alpha-mannosidase activity is compromised in siRNA-treated cells. Determination of alteration of siRNA treatment, glycans recovered from membrane glycoproteins are fluorescence-labelled and analysed by HPLC
-
Sr2+
-
inhibition at 1 mM
swainsonine
ZnCl2
-
92% inhibition by 1 mM, 56% inhibition by 0.01 mM
[6-(3-methylbutoxy)-3-oxo-3,6-dihydro-2H-pyran-2-yl]acetonitrile
-
-
[6-(3-methylbutoxy)-3-oxo-3,6-dihydro-2H-pyran-2-yl]methyl 2,2-dimethylpropanoate
-
-
[[(3S,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)piperidin-2-ylidene]amino] N-(4-chlorophenyl)carbamate
-
-
additional information
-